Tonix Pharma Moves to Nasdaq Global Select
Tonix Pharmaceuticals has uplisted to the Nasdaq Global Select Market. The move to the higher-tier exchange is a milestone for the company that signals growth in its drug and vaccine pipeline.
The move to the Nasdaq Global Select Market on March 3, 2026, places Tonix among companies meeting the highest financial, liquidity, and corporate governance standards. This elevated status can increase visibility to investors, potentially securing more funding for its scientific research. The company's central nervous system (CNS) pipeline includes TONMYA™, a recently approved treatment for fibromyalgia. Tonix is now exploring its potential in other areas, running Phase 2 clinical trials for major depressive disorder and acute stress disorder. Beyond CNS, Tonix develops immunology and infectious disease therapies. Its pipeline features TNX-1500, a monoclonal antibody designed to prevent kidney transplant rejection which has completed Phase 1 trials, and TNX-4800 for preventing Lyme disease. Bringing a drug like the anti-CD40L antibody TNX-1500 from concept to clinical trial involves years of lab work. "Biotech" or research roles are filled by scientists with degrees in molecular biology or immunology who discover and test these molecules in preclinical studies before they ever reach a human patient. As research progresses, massive amounts of data are generated from genomics, proteomics, and clinical trials. This is where tech roles like bioinformatics and computational biology come in. Professionals in these fields use computer science and statistical skills to analyze complex biological data, identifying patterns that can lead to new drug targets or explain trial outcomes. Once a drug is ready for human testing, clinical research careers become central. Professionals in these patient-facing roles design and manage clinical trials, like the planned Phase 2/3 study for the Lyme disease antibody. They ensure patient safety, manage data collection, and navigate the rigorous FDA approval process. These paths require different training: a Ph.D. could lead a lab developing a vaccine, while a medical doctor (M.D.) might oversee the clinical trial for that vaccine. A career in bioinformatics might start with a bachelor's or master's degree in computational biology, blending lab science knowledge with coding skills.
